Detalhe da pesquisa
1.
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.
Cancer;
120(3): 390-8, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE
| Jan 2014
| ID: mdl-24452673
Mostrar mais
Texto completo
Documentos relacionados
2.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol;
14(2): 149-58, 2013 Feb.
Artigo
em Inglês
| MEDLINE
| Jan 2013
| ID: mdl-23306100
3.
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Lancet Oncol;
12(7): 673-80, 2011 Jul.
Artigo
em Inglês
| MEDLINE
| Jun 2011
| ID: mdl-21664867
4.
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
JAMA Oncol;
2019 Jan 31.
Artigo
em Inglês
| MEDLINE
| Fev 2019
| ID: mdl-30703190
5.
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Eur Urol;
70(2): 256-62, 2016 08.
Artigo
em Inglês
| MEDLINE
| 2016
| ID: mdl-26610858
6.
A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
Clin Genitourin Cancer;
12(1): 50-4, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| 2014
| ID: mdl-24268852
7.
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.
Clin Genitourin Cancer;
7(2): E28-33, 2009 Aug.
Artigo
em Inglês
| MEDLINE
| Ago 2009
| ID: mdl-19692319